<DOC>
	<DOCNO>NCT01599013</DOCNO>
	<brief_summary>This study assess combination well know cytotoxics novel anti-cancer agent could administer monotherapy without renal toxicity patient renal impairment presenting advance metastatic urothelial carcinoma previously treat platinum-based regimen . The intent study clarify benefit/risk ratio two promising association cytotoxics include novel therapeutic agent , vinflunine : vinflunine-gemcitabine vinflunine-carboplatin .</brief_summary>
	<brief_title>JAVLOR Association Study CDDP-unfit Patients With Advanced Transitional Cell Carcinoma : Gemcitabine Versus Carboplatin</brief_title>
	<detailed_description>Gemcitabine carboplatin study used anticancer agent cisplatin-unfit patient advance urothelial carcinoma . Both agent previously demonstrate clinical activity single agent and/or part combination regimen patient advanced metastatic disease even clinical benefit survival remain limited set population . The purpose study test randomize trial enrol patient renal impairment moderate congestive heart failure two combination novel cytotoxic agent , vinflunine , one gemcitabine another carboplatin order determine promise combination first line treatment advanced/metastatic urothelial carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Man woman age ≥ 18 year &lt; 80 year Signed write informed consent Histologically confirm diagnosis locally advance metastatic predominantly transitional cell carcinoma urothelium ( TCCU ) Ineligibility cisplatinbased therapy least one follow two medical condition : Calculated creatinine clearance ( CockcroftGault formula ) &lt; 60 mL/min New York Heart Association Classification Stage IIIII Congestive Heart Failure ( document medical history ) `` Measurable '' disease least one unidimensional lesion accord RECIST guideline ( version 1.1 ) ECOG performance status 0 1 Estimated life expectancy least 12 week Patient without prior systemic anticancer therapy unless administer neoadjuvant adjuvant chemotherapy ( CT ) TCCU patient document relapse ≥ 6 month last dose CT ( prior intravesical CT allow ) Adequate bone marrow hepatic function evidence : Absolute Neutrophil Count ≥ 2,000/mm3 ( ≥ 2.0 x 109/L ) Haemoglobin ≥ 10 g/dL Platelet count ≥ 100,000/mm3 Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Transaminases ≤ 2.5 x ULN [ ≤ 5 x ULN case liver metastasis ] Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition assess patient registration trial ECOG performance status ≥ 2 Woman pregnant lactate positive pregnancy test inclusion ; woman childbearing potential use unwilling unable use acceptable method avoid pregnancy 2 month precede start study treatment , entire study period 3 month last dose study treatment ; sexually active fertile man use effective birth control study 6 month last dose study treatment partner woman childbearing potential Known brain metastasis leptomeningeal involvement . Peripheral neuropathy Grade ≥ 2 NCI CTC Prior radiation ≥ 30 % bone marrow complete &lt; 30 day ago without full recovery toxicities Other serious illness medical condition include : Infection require systemic antiinfective therapy Any medical condition might control , instance patient unstable angina , patient myocardial infarction within 6 month uncontrolled diabetes Prior systemic chemotherapy advance metastatic disease neoadjuvant/adjuvant chemotherapy complete &lt; 6 month document progression Patient receive investigational drug anticancer therapy within 30 day randomisation Other malignancy except adequately treat basal carcinoma skin , insitu cervix carcinoma , localised prostate cancer limit risk recurrence ( pT ≤ 2b , Gleason score ≤ 7 ) incidentally discover lead treatment apart prostatectomy , tumor disease free interval ≥ 5 year Inadequate renal function define serum creatinine clearance &lt; 30 mL/min ( CockcroftGault formula ) Known hypersensitivity study drug drug similar chemical structure Patients require treatment ketoconazole , itraconazole , ritonavir , amprenavir , indinavir , rifampicin ( potent CYP3A4 inhibitor inducer ) phenytoin Any concurrent chronic system immune therapy previous organ allograft Electrocardiogram ( ECG ) significant modification suggest high risk occurrence acute clinical event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>urothelial carcinoma</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>vinflunine</keyword>
	<keyword>transitional cell carcinoma</keyword>
	<keyword>advanced metastatic</keyword>
	<keyword>unfit</keyword>
	<keyword>ineligible cisplatin</keyword>
	<keyword>renal impairment</keyword>
	<keyword>renal insufficiency</keyword>
	<keyword>urologic neoplasm</keyword>
	<keyword>urogenital neoplasm</keyword>
	<keyword>urinary neoplasm</keyword>
	<keyword>cisplatin</keyword>
	<keyword>tubulin inhibitor</keyword>
</DOC>